Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tabirafusp tedromer - Kodiak Sciences

Next Previous
Drug Profile

Tabirafusp tedromer - Kodiak Sciences

Alternative Names: KSI-501; KSI-501ABC

Latest Information Update: 10 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kodiak Sciences
  • Class Anti-inflammatories; Biopolymers; Drug conjugates; Eye disorder therapies; Immunoconjugates; Recombinant fusion proteins
  • Mechanism of Action Interleukin 6 inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Wet age-related macular degeneration
  • Phase I Diabetic macular oedema
  • Preclinical Dry age-related macular degeneration
  • No development reported Uveitis

Most Recent Events

  • 23 Aug 2024 Phase-III clinical trials in Wet age-related macular degeneration (Combination therapy, Treatment-naive) in Puerto Rico (Intravitreous) (NCT06556368)
  • 14 Aug 2024 Phase-III clinical trials in Wet age-related macular degeneration (Treatment-naive, Combination therapy) in USA (Intravitreous) (NCT06556368)
  • 14 Aug 2024 Kodiak Sciences plans to submit marketing authorization application for Wet age-related macular degeneration

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top